US exempts India and 19 nations from 100% tariff on certain speciality drugs: Report
Economic Times 1 hr ago·28 Sept 2026, 4:46 pm
The United States has exempted India and 19 other nations from a proposed 100% tariff on certain specialty drugs and their ingredients. This decision follows President Donald Trump's proclamation to impose steep tariffs on specific patented pharmaceuticals. The exemption applies to drugs used to treat rare diseases and infertility, as well as their components. The move is seen as a significant win for India's pharmaceutical sector, which is a major global supplier of generic and active pharmaceutical ingredients (APIs).
For investors, this development is a positive signal for the broader Indian market. It reduces immediate trade uncertainty for the country's largest export industry. The removal of such a high tariff could help maintain the competitiveness of Indian pharma companies in the US market. Investors should monitor how this policy impacts the export volumes and profit margins of key pharmaceutical firms in the coming quarters.
Excerpt from Economic Times
The United States has announced it will exempt certain speciality drugs and ingredients imported from India and 19 other countries from tariffs. This decision follows US President Donald Trump's proclamation imposing a 100% tariff on specified patented pharmaceuticals. Drugs intended for rare diseases and infertility,…Read the original at Economic Times
Key takeaways
- Category: Economy.
- AI reads the tone as positive (potentially bullish) for the stock.
- Flagged as a high-impact, market-moving story.
Why it matters
This is a high-impact development and could move the stock. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.
